Classic Review,0.6 mg (= 10 clicks) by S/C injection daily

Understanding the liraglutide monographie Canada is crucial for healthcare professionals and patients alike when considering this important medication. This article delves into the specifics of liraglutide, drawing from official health authority guidelines and clinical data. We will explore its indications, dosage, potential warnings, and its role in managing specific health conditions within the Canadian context.

Liraglutide, a GLP-1 derivative, is a prescription medication available in Canada under various brand names, most notably Saxenda® and Victoza®. Its primary mechanism of action involves mimicking the effects of the naturally occurring human glucagon-like peptide-1 (GLP-1) hormone. This leads to a cascade of beneficial effects, including increased insulin secretion, reduced glucagon secretion, slowed gastric emptying, and enhanced satiety, all of which contribute to its therapeutic applications.

Indications for Liraglutide in Canada

In Canada, liraglutide is approved for two main therapeutic areas: chronic weight management and type 2 diabetes mellitus.

Chronic Weight Management

For individuals struggling with weight management, liraglutide is indicated as an adjunct to a reduced-calorie diet and increased physical activity. This means it is not a standalone solution but works best as part of a comprehensive lifestyle modification program. The SAXENDA® (liraglutide injection) monograph specifies its use for chronic weight management in adults. It is also approved for chronic weight management in pediatric patients aged 10 years and above, as indicated by Health Canada's product assessments. The general criteria for its use in obesity management often involve a Body Mass Index (BMI) of ≥ 30 kg/m² or a BMI of ≥ 27 kg/m² with adiposity-related complications.

Type 2 Diabetes Mellitus

Liraglutide is also a valuable tool in managing type 2 diabetes. It is used as an adjunct to diet and exercise to improve glycemic control. This includes its use in adults and pediatric patients aged 10 years and above with type 2 diabetes mellitus. The Victoza® (liraglutide injection) product monograph details its role in improving blood glucose levels by increasing the body's response to blood sugar, thereby lowering it. For patients with type 2 diabetes, liraglutide can be initiated at a dose of 0.6 mg (= 10 clicks) by S/C injection daily before breakfast, with subsequent dose adjustments based on tolerance and efficacy.

Liraglutide Dosages and Administration

The dosage and administration of liraglutide are critical for both efficacy and safety. The treatment typically begins with a low dose and is gradually increased.

* Weight Management (Saxenda®): The typical maintenance dose for weight management is 3 mg subcutaneously daily. The dosing schedule often starts at 0.6 mg daily for the first week, then increases weekly to 1.2 mg, 1.8 mg, 2.4 mg, and finally 3.0 mg.

* Type 2 Diabetes (Victoza®): For type 2 diabetes, the dose is usually started at 0.6 mg once daily for one week, then increased to 1.2 mg once daily. Further increases to 1.8 mg once daily may be considered based on clinical response and tolerability.

Liraglutide is administered via subcutaneous injection. The injection sites commonly include the abdomen, thigh, or upper arm.

Important Warnings and Precautions

The liraglutide monographie Canada and product information from Health Canada highlight several important warnings and precautions that patients and healthcare providers must be aware of.

* Thyroid C-cell Tumors: A significant warning associated with liraglutide is the risk of thyroid C-cell tumors. Studies in rodents have shown an increased incidence of these tumors. While the relevance to humans is not fully established, it is a contraindication for use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

* Pancreatitis: There is a potential risk of pancreatitis, an inflammation of the pancreas. Patients experiencing symptoms such as severe abdominal pain, which may radiate to the back, with or without vomiting, should seek immediate medical attention.

* Gallbladder Disease: Rapid weight loss, which can occur with liraglutide therapy, may increase the risk of gallstones and gallbladder disease.

* Renal Impairment: Caution and dose adjustments may be necessary for patients with renal impairment.

* Drug Interactions: Specific drug-drug interactions with liraglutide have been studied. While generally well-tolerated, healthcare providers should review all concomitant medications to avoid potential adverse effects. For example, studies were performed at a steady state with liraglutide 1.8 mg/day for certain drug interactions.

Liraglutide in the Canadian Healthcare Landscape

The availability